Long term survival and complications after liver transplantation in patients with chronic hepatitis B

Maria Yataco, Hugo Bonatti, Victor Machicao, Julio C Mendez, John Stauffer, Justin H Nguyen, Marwan Ghabril, Jaime Aranda-Michel, Rolland Dickson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Following introduction of effective antiviral prophylaxis, recurrent hepatitis B after liver transplantation (LT) has become a rare event. Material/Methods: From 1998 to 2001, 402 patients underwent 467 LTs at our center including 24 individuals (28 LTs) with chronic hepatitis B. All patients received HBIg prophylaxis; 23 in combination with lamivudine and one (YMDD mutant) received adefovir. Results: Eleven patients (46%) had HCC (five outside the Milan criteria); only one died from tumor recurrence four years post LT. The one-year graft and patient survival were 87% and 92%, respectively. Currently 19 patients (79%) are alive with well functioning grafts (minimum follow up of >7 years). No patient developed recurrent hepatitis B; 12 currently receive lamivudine/HBIg, 3 lamivudine monotherapy, 3 discontinued antivirals. Follow up liver biopsies showed minimally active or no active hepatitis and negative HBV immunostains in all patients. Long term comorbid conditions included hypertension (77%), chronic renal failure (50%), diabetes mellitus (77%), hyperlipidemia (36%), obesity (55%), malignancies (37%) and neuropsychiatric disorders (55%). During the study period, 24 individuals (6%) were transplanted for chronic hepatitis B as opposed to only 38 individuals (3.3%) from 2002 to 6/2008 (1298 LTs in 1162 patients). Conclusions: LT for chronic HBV produced excellent long term results despite inclusion of patients with HCC outside the Milan criteria. Long term medical complications must be considered. Indication for LT for chronic HBV is declining but long term development of resistance remains a matter of concern.

Original languageEnglish (US)
Pages (from-to)27-34
Number of pages8
JournalAnnals of Transplantation
Volume15
Issue number2
StatePublished - 2010

Fingerprint

Chronic Hepatitis B
Liver Transplantation
Survival
Lamivudine
Hepatitis B
Antiviral Agents
Graft Survival
Hyperlipidemias
Hepatitis
Chronic Kidney Failure
Neoplasms
Diabetes Mellitus
Obesity
Hypertension
Transplants
Biopsy
Recurrence
Liver

Keywords

  • HBV
  • Hepatocellular cancer
  • Immunosuppression
  • Lamivudine
  • Liver transplant

ASJC Scopus subject areas

  • Transplantation
  • Medicine(all)

Cite this

Long term survival and complications after liver transplantation in patients with chronic hepatitis B. / Yataco, Maria; Bonatti, Hugo; Machicao, Victor; Mendez, Julio C; Stauffer, John; Nguyen, Justin H; Ghabril, Marwan; Aranda-Michel, Jaime; Dickson, Rolland.

In: Annals of Transplantation, Vol. 15, No. 2, 2010, p. 27-34.

Research output: Contribution to journalArticle

Yataco, Maria ; Bonatti, Hugo ; Machicao, Victor ; Mendez, Julio C ; Stauffer, John ; Nguyen, Justin H ; Ghabril, Marwan ; Aranda-Michel, Jaime ; Dickson, Rolland. / Long term survival and complications after liver transplantation in patients with chronic hepatitis B. In: Annals of Transplantation. 2010 ; Vol. 15, No. 2. pp. 27-34.
@article{1ff9108d6ba84d588129dfb1027ea06f,
title = "Long term survival and complications after liver transplantation in patients with chronic hepatitis B",
abstract = "Background: Following introduction of effective antiviral prophylaxis, recurrent hepatitis B after liver transplantation (LT) has become a rare event. Material/Methods: From 1998 to 2001, 402 patients underwent 467 LTs at our center including 24 individuals (28 LTs) with chronic hepatitis B. All patients received HBIg prophylaxis; 23 in combination with lamivudine and one (YMDD mutant) received adefovir. Results: Eleven patients (46{\%}) had HCC (five outside the Milan criteria); only one died from tumor recurrence four years post LT. The one-year graft and patient survival were 87{\%} and 92{\%}, respectively. Currently 19 patients (79{\%}) are alive with well functioning grafts (minimum follow up of >7 years). No patient developed recurrent hepatitis B; 12 currently receive lamivudine/HBIg, 3 lamivudine monotherapy, 3 discontinued antivirals. Follow up liver biopsies showed minimally active or no active hepatitis and negative HBV immunostains in all patients. Long term comorbid conditions included hypertension (77{\%}), chronic renal failure (50{\%}), diabetes mellitus (77{\%}), hyperlipidemia (36{\%}), obesity (55{\%}), malignancies (37{\%}) and neuropsychiatric disorders (55{\%}). During the study period, 24 individuals (6{\%}) were transplanted for chronic hepatitis B as opposed to only 38 individuals (3.3{\%}) from 2002 to 6/2008 (1298 LTs in 1162 patients). Conclusions: LT for chronic HBV produced excellent long term results despite inclusion of patients with HCC outside the Milan criteria. Long term medical complications must be considered. Indication for LT for chronic HBV is declining but long term development of resistance remains a matter of concern.",
keywords = "HBV, Hepatocellular cancer, Immunosuppression, Lamivudine, Liver transplant",
author = "Maria Yataco and Hugo Bonatti and Victor Machicao and Mendez, {Julio C} and John Stauffer and Nguyen, {Justin H} and Marwan Ghabril and Jaime Aranda-Michel and Rolland Dickson",
year = "2010",
language = "English (US)",
volume = "15",
pages = "27--34",
journal = "Annals of Transplantation",
issn = "1425-9524",
publisher = "International Scientific Information, Inc.",
number = "2",

}

TY - JOUR

T1 - Long term survival and complications after liver transplantation in patients with chronic hepatitis B

AU - Yataco, Maria

AU - Bonatti, Hugo

AU - Machicao, Victor

AU - Mendez, Julio C

AU - Stauffer, John

AU - Nguyen, Justin H

AU - Ghabril, Marwan

AU - Aranda-Michel, Jaime

AU - Dickson, Rolland

PY - 2010

Y1 - 2010

N2 - Background: Following introduction of effective antiviral prophylaxis, recurrent hepatitis B after liver transplantation (LT) has become a rare event. Material/Methods: From 1998 to 2001, 402 patients underwent 467 LTs at our center including 24 individuals (28 LTs) with chronic hepatitis B. All patients received HBIg prophylaxis; 23 in combination with lamivudine and one (YMDD mutant) received adefovir. Results: Eleven patients (46%) had HCC (five outside the Milan criteria); only one died from tumor recurrence four years post LT. The one-year graft and patient survival were 87% and 92%, respectively. Currently 19 patients (79%) are alive with well functioning grafts (minimum follow up of >7 years). No patient developed recurrent hepatitis B; 12 currently receive lamivudine/HBIg, 3 lamivudine monotherapy, 3 discontinued antivirals. Follow up liver biopsies showed minimally active or no active hepatitis and negative HBV immunostains in all patients. Long term comorbid conditions included hypertension (77%), chronic renal failure (50%), diabetes mellitus (77%), hyperlipidemia (36%), obesity (55%), malignancies (37%) and neuropsychiatric disorders (55%). During the study period, 24 individuals (6%) were transplanted for chronic hepatitis B as opposed to only 38 individuals (3.3%) from 2002 to 6/2008 (1298 LTs in 1162 patients). Conclusions: LT for chronic HBV produced excellent long term results despite inclusion of patients with HCC outside the Milan criteria. Long term medical complications must be considered. Indication for LT for chronic HBV is declining but long term development of resistance remains a matter of concern.

AB - Background: Following introduction of effective antiviral prophylaxis, recurrent hepatitis B after liver transplantation (LT) has become a rare event. Material/Methods: From 1998 to 2001, 402 patients underwent 467 LTs at our center including 24 individuals (28 LTs) with chronic hepatitis B. All patients received HBIg prophylaxis; 23 in combination with lamivudine and one (YMDD mutant) received adefovir. Results: Eleven patients (46%) had HCC (five outside the Milan criteria); only one died from tumor recurrence four years post LT. The one-year graft and patient survival were 87% and 92%, respectively. Currently 19 patients (79%) are alive with well functioning grafts (minimum follow up of >7 years). No patient developed recurrent hepatitis B; 12 currently receive lamivudine/HBIg, 3 lamivudine monotherapy, 3 discontinued antivirals. Follow up liver biopsies showed minimally active or no active hepatitis and negative HBV immunostains in all patients. Long term comorbid conditions included hypertension (77%), chronic renal failure (50%), diabetes mellitus (77%), hyperlipidemia (36%), obesity (55%), malignancies (37%) and neuropsychiatric disorders (55%). During the study period, 24 individuals (6%) were transplanted for chronic hepatitis B as opposed to only 38 individuals (3.3%) from 2002 to 6/2008 (1298 LTs in 1162 patients). Conclusions: LT for chronic HBV produced excellent long term results despite inclusion of patients with HCC outside the Milan criteria. Long term medical complications must be considered. Indication for LT for chronic HBV is declining but long term development of resistance remains a matter of concern.

KW - HBV

KW - Hepatocellular cancer

KW - Immunosuppression

KW - Lamivudine

KW - Liver transplant

UR - http://www.scopus.com/inward/record.url?scp=77954628255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954628255&partnerID=8YFLogxK

M3 - Article

C2 - 20657516

AN - SCOPUS:77954628255

VL - 15

SP - 27

EP - 34

JO - Annals of Transplantation

JF - Annals of Transplantation

SN - 1425-9524

IS - 2

ER -